The FINANCIAL — Pfizer announced that its Market Authorisation Application for tofacitinib, a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis , has been validated by the European Medicines Agency.
Validation means that the EMA has confirmed that the application is complete and the agency is beginning its review procedure.
Pfizer studied tofacitinib for moderate-to-severe active RA in the Phase 3 ORAL program. The ORAL Trials program consists of five studies for which data needed for registration are complete and one ongoing Phase 3 clinical trial. In addition, tofacitinib is being investigated in two ongoing long-term open-label extension studies. Close to 5,000 RA patients at more than 350 sites in 35 countries worldwide have been treated with tofacitinib in clinical trials.
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
Discussion about this post